Scarica l'app Stockscreener
24.28
1.18%
-0.29
Dopo l'orario di chiusura:
24.08
-0.20
-0.82%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ADPT Giù?
Forum
Previsione
Precedente Chiudi:
$24.57
Aprire:
$24.06
Volume 24 ore:
1.40M
Relative Volume:
0.48
Capitalizzazione di mercato:
$3.87B
Reddito:
$295.41M
Utile/perdita netta:
$-49.64M
Rapporto P/E:
-74.16
EPS:
-0.3274
Flusso di cassa netto:
$-29.54M
1 W Prestazione:
-3.61%
1M Prestazione:
-1.10%
6M Prestazione:
+47.69%
1 anno Prestazione:
+86.48%
Intervallo 1D:
$23.94
$24.40
Intervallo di 1 settimana:
$23.84
$25.36
Portata 52W:
$12.00
$26.87
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Nome
Adaptive Biotechnologies Corp
Settore
Industria
Telefono
206-659-0067
Indirizzo
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT vs TMO, DHR, NTRA, IQV, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
24.28 | 4.06B | 295.41M | -49.64M | -29.54M | -0.3274 |
TMO
Thermo Fisher Scientific Inc
|
613.78 | 232.03B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
207.66 | 151.78B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
328.18 | 46.82B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
267.77 | 42.15B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
150.86 | 44.14B | 7.23B | 1.41B | 1.09B | 4.979 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-02 | Ripresa | Morgan Stanley | Equal-Weight |
| 2025-09-30 | Iniziato | Guggenheim | Buy |
| 2025-06-18 | Iniziato | Craig Hallum | Buy |
| 2025-03-21 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-12-21 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | Iniziato | Credit Suisse | Underperform |
| 2022-06-03 | Iniziato | Piper Sandler | Neutral |
| 2022-02-16 | Reiterato | BTIG Research | Buy |
| 2022-02-16 | Reiterato | BofA Securities | Buy |
| 2022-02-16 | Reiterato | Goldman | Neutral |
| 2022-02-16 | Reiterato | JP Morgan | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-03-03 | Downgrade | Goldman | Buy → Neutral |
| 2020-10-08 | Ripresa | BTIG Research | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-06-03 | Iniziato | Goldman | Buy |
| 2019-07-23 | Iniziato | BTIG Research | Buy |
| 2019-07-22 | Iniziato | BofA/Merrill | Buy |
| 2019-07-22 | Iniziato | Cowen | Outperform |
| 2019-07-22 | Iniziato | Goldman | Neutral |
| 2019-07-22 | Iniziato | Guggenheim | Buy |
| 2019-07-22 | Iniziato | William Blair | Outperform |
Mostra tutto
Adaptive Biotechnologies Corp Borsa (ADPT) Ultime notizie
Adaptive Biotechnologies Stock Has Doubled in the Past Year. Here’s What Could Come Next. - inkl
Bank of America Corp DE Acquires 421,645 Shares of Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Adaptive Biotechnologies director Robert Hershberg sells $748k in shares - Investing.com
Adaptive Biotechnologies director Robert Hershberg sells $748k in shares By Investing.com - Investing.com South Africa
Adaptive Biotechnologies (NASDAQ:ADPT) Director Robert Hershberg Sells 30,664 Shares of Stock - MarketBeat
Adaptive Biotechnologies Director Robert Hershberg Executes Stock Option and Sells Shares - Kalkine Media
Adaptive Biotech (NASDAQ: ADPT) ex-officer to sell 402,160 shares - Stock Titan
Adaptive Biotechnologies (NASDAQ: ADPT) director exercises option at $6.32 strike - Stock Titan
Adaptive Biotechnologies director Neupert sells $3.1m in stock By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies CEO Chad Robins sells $14.88m in shares By Investing.com - Investing.com India
Adaptive Biotechnologies director Neupert sells $3.1m in stock - Investing.com
Adaptive Biotechnologies CEO Chad Robins sells $14.88m in shares - Investing.com
Adaptive Biotechnologies (NASDAQ:ADPT) CEO Chad Robins Sells 278,676 Shares - MarketBeat
Adaptive Biotechnologies (ADPT) CEO sells 600K shares after exercising options - Stock Titan
Adaptive Biotechnologies (ADPT) director sells stock after option exercise - Stock Titan
Adaptive Biotechnologies (NASDAQ: ADPT) ex-officer plans new share sale - Stock Titan
Adaptive Biotechnologies stock hits 52-week high at 26.16 USD By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies (NASDAQ:ADPT) Sets New 1-Year HighHere's What Happened - MarketBeat
Adaptive Biotechnologies stock hits 52-week high at 26.16 USD - Investing.com
66,000 Shares in Adaptive Biotechnologies Corporation $ADPT Bought by Handelsbanken Fonder AB - MarketBeat
Adaptive Biotechnologies (NASDAQ: ADPT) director plans to resell 30,664 shares - Stock Titan
Adaptive Biotechnologies (NASDAQ: ADPT) insider plans more sales after $7.96M already sold - Stock Titan
Adaptive Biotechnologies (ADPT) ex-officer plans cashless option share sale - Stock Titan
Adaptive Biotech co-founder raises $15M for new startup to rethink how AI trains on science - GeekWire
Adaptive Biotechnologies (NASDAQ: ADPT) insider plans multimillion stock sale - Stock Titan
Adaptive Biotechnologies (ADPT) plans multi-million-dollar stock sale for 2026 - Stock Titan
Adaptive Biotechnologies (NASDAQ: ADPT) lines up six-figure share sale for 2026 - Stock Titan
Dimensional Fund Advisors LP Cuts Stock Holdings in Adaptive Biotechnologies Corporation $ADPT - MarketBeat
576,266 Shares in Adaptive Biotechnologies Corporation $ADPT Bought by Wasatch Advisors LP - MarketBeat
Adaptive Biotechnologies (ADPT) Stock Looks Fair On Cash Flow Yet Rich On Sales - simplywall.st
Adaptive Biotechnologies CCO Susan Bobulsky sells $75,000 in shares By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies CCO Susan Bobulsky sells $75,000 in shares - Investing.com
Adaptive Biotechnologies (NASDAQ:ADPT) Insider Susan Bobulsky Sells 3,000 Shares of Stock - MarketBeat
Adaptive Biotechnologies (ADPT) CCO Bobulsky sells 3,000 shares under plan - Stock Titan
Adaptive Biotechnologies Corp (ADPT) Stock Analysis: Navigating the Growth Path with a 21.5% Revenue Surge - DirectorsTalk Interviews
Adaptive Biotechnologies (NASDAQ:ADPT) Sets New 12-Month HighHere's Why - MarketBeat
ADPT (ADPT) insider outlines Form 144 sale of 3,000 shares - stocktitan.net
Adaptive Biotechnologies stock hits 52-week high at 25.04 USD By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies stock hits 52-week high at 25.04 USD - Investing.com
Renaissance Technologies LLC Acquires Shares of 239,800 Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Adaptive Biotechnologies Corp (ADPT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Adaptive Biotechnologies Corp (ADPT) Stock News Today - TradingKey
Adaptive Biotechnologies Corp (1HM) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Adaptive Biotechnologies Corp (1HM) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Adaptive Biotechnologies Corp (1HM) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Adaptive Biotechnologies Corp (1HM) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Adaptive Biotechnologies Corp (1HM) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Adaptive Biotechnologies Corp (1HM) Q4 2024 Earnings ReportResults, Call & Slides - tipranks.com
Adaptive Biotechnologies Corp (1HM) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Adaptive Biotechnologies Corp (ADPT) Shares Fall 4.1% -- GF Value Says Still Overvalued - GuruFocus
Adaptive Biotechnologies Corp Q2 2026: Revenue $71.6M, EPS $(0.25) — 10-Q Summary - TradingView
Adaptive Biotechnologies Corp Azioni (ADPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.39%
1.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):